Table 2.
Serum values at baseline and throughout follow-up on TRT
Baseline
0
–
3 months
P
-value
3
–
6 months
P
-value
6
–
12 months
P
-value
T (ng dl
±
1
)(n
)
All patients
178.0 (88.0–263.5) (13)
331.5 (178.5–738.8) (10)
0.028
512.0 (396.0–1365.5) (5)
0.043
667.5 (472.8–772.5) (10)
0.005
Gleason 6
263.5 (151.5–290.8) (4)
504.5 (220.5–602.8) (2)
512.0 (1)
709.0 (141.0–757.0) (3)
Gleason 7
178.0 (86.0–238.0) (7)
476.0 (178.5–1161.8) (6)
656.0 (464.0–2075) (3)
626.0 (558.0–768.0) (5)
Gleason 8
65.0 (30.0–67.5) (2)
268.0 (125.3–376.8) (2)
328.0 (1)
713.0 (243.8–825.8) (2)
FT (pg ml
±
1
)(n
)
All patients
5.1 (3.6–5.8) (8)
4.5 (3.7–17.7) (7)
0.500
13.8 (6.0–20.5) (4)
0.109
16.2 (3.4–19.6) (6)
0.068
Gleason 6
5.4 (4.8–5.9) (3)
19.9 (1)
15.7 (1)
9.4 (2.6–13.0) (2)
Gleason 7
5.1 (3.6–7.7) (4)
6.2 (3.9–15.3) (4)
17.0 (8.9–18.6) (2)
18.0 (12.8–16.2) (2)
Gleason 8
0.7 (1)
3.6 (2.1–3.3) (2)
4.0 (1)
12.5 (2.5–16.3) (2)
E (pg ml
±
1
)(n
)
All patients
18.0 (11.0–35.0) (9)
40.0 (20.0–52.0) (7)
0.080
30.0 (19.0–38.0) (3)
1.000
27.0 (21.0–48.5) (6)
0.465
Gleason 6
30.0 (12.0–57.0) (3)
64.0 (1)
30.0 (1)
21.0 (13.5–32.3) (2)
Gleason 7
20.5 (12.0–35.8) (4)
42.5 (16.8–50.3) (4)
38.0 (1)
40.0 (22.0–74.0) (3)
Gleason 8
8.5 (0.0–12.8) (2)
25.5 (15.0–23.3) (2)
19.0 (1)
30.0 (1)
SHBG (nmol l
±
1
)(n
)
All patients
31.5 (19.3–36.5) (8)
28.0 (18.0–40.0) (7)
0.102
17.0 (11.3–54.3) (4)
0.655
34.0 (19.5–56.8) (6)
0.255
Gleason 6
33.0 (30.0–37.0) (3)
21.0 (1)
12.0 (1)
27.5 (15.0–35.5) (2)
Gleason 7
22.5 (12.3–33.5) (4)
23.0 (15.0–34.0) (4)
16.5 (8.3–23.5) (2)
25.5 (13.5–31.8) (2)
Gleason 8
38.0 (1)
53.5 (30.0–50.3) (2)
65.0 (1)
65.5 (36.0–62.3) (2)
Hgb (g dl
±
1
)(n
)
All patients
15.8 (15.0–16.2) (3)
14.9 (13.9–17.2) (4)
13.5 (12.8–15.7) (3)
15.1 (13.8–15.4) (6)
Gleason 6
—
15.2 (1)
13.5 (1)
14.8 (14.3–15.3) (3)
Gleason 7
16.0 (11.9–12.2) (2)
14.6 (13.6–17.9) (3)
12.8 (1)
13.8 (9.1–16.0) (2)
Gleason 8
15.0 (1)
—
15.7 (1)
15.5 (1)
Hct (%) (
n)
All patients
47.9 (42.8–49.0) (3)
43.9 (40.2–49.4) (4)
39.1 (37.9–49.3) (3)
44.9 (40.1–45.9) (6)
Gleason 6
—
45.3 (1)
39.1 (1)
44.8 (41.3–46.6) (3)
Gleason 7
48.5 (35.9–40.2) (2)
42.4 (39.5–50.8) (3)
37.9 (1)
41.1 (27.5–46.9) (2)
Gleason 8
42.8 (1)
—
49.3 (1)
44.9 (1)
PSA (ng ml
±
1
)(n
)
All patients
0.30 (0.06–0.95) (13)
0.38 (0.10–1.36) (10)
0.260
0.32 (0.19–1.17) (5)
0.144
0.44 (0.09–1.12) (9)
0.735
Gleason 6
0.58 (0.07–1.23) (4)
0.71 (0.08–1.23) (2)
0.32 (1)
0.20 (0.03–0.93) (3)
Gleason 7
0.40 (0.09–0.96) (7)
0.44 (0.10–2.07) (6)
0.29 (0.09–1.75) (3)
0.70 (0.09–2.01) (4)
Gleason 8
0.15 (0.01–0.23) (2)
0.29 (0.07–0.37) (2)
0.59 (1)
0.52 (0.33–0.45) (2)
12
–
18 months
P
-value
18
–
24 months
P
-value
24
–
30 months
P
-value
4
30 months
P
-value
T (ng dl
±
1
)(n
)
All patients
458.0 (228.8–755.5) (10)
0.013
240.0 (172.0–461.5) (9)
0.109
368.0 (281.3–591.0) (8)
0.012
228.0 (169.8–657.0) (6)
0.463
Gleason 6
654.0 (392.3–863.3) (4)
326.0 (110.3–565.5) (2)
531.0 (312.0–645.0) (3)
262.0 (194.0–699.0) (3)
Gleason 7
245.0 (115.5–518.0) (5)
219.0 (120.0–329.0) (5)
271.0 (151.0–329.0) (3)
371.5 (75.0–564.5)0 (2)
Gleason 8
781.0 (1)
395.0 (192.0–400.5) (2)
509.0 (305.3–458.3) (2)
193 (1)
FT (pg ml
±
1
)(n
)
All patients
10.1 (5.7–15.0) (8)
0.138
4.7 (4.0–7.0) (8)
0.753
5.4 (4.9–8.0) (7)
0.144
3.2 (2.1–9.3) (6)
1.000
Gleason 6
13.8 (9.8–18.1) (4)
5.9 (2.0–10.9) (2)
9.2 (4.1–13.8) (2)
3.3 (3.0–13.6) (3)
Gleason 7
6.0 (4.3–9.8) (4)
4.7 (4.1–5.2) (4)
4.9 (2.4–5.1) (3)
4.6 (0.9–7.4) (2)
Gleason 8
—
5.8 (3.0–5.7) (2)
6.8 (4.3–6.0) (2)
2.4 (1)
E (pg ml
±
1
)(n
)
All patients
40.0 (17.0–44.5) (9)
0.345
17.5 (12.8–27.5) (8)
0.933
19.0 (14.8–21.5) (8)
0.574
20.0 (17.8–24.0) (6)
0.279
Gleason 6
40.0 (24.3–64.0) (4)
16.0 (9.0–25.0) (2)
14.0 (14.0–18.0) (3)
23.0 (11.0–27.0) (3)
Gleason 7
27.5 (11.3–46.8) (4)
17.5 (15.3–31.0) (4)
20.0 (17.0–22.0) (3)
20.0 (15.0–20.5) (2)
Gleason 8
28.0 (1)
19.5 (6.8–22.5) (2)
26.0 (15.0–24.0) (2)
20.0 (1)
SHBG (nmol l
±
1
)(n
)
All patients
35.0 (26.0–41.5) (9)
0.091
38.5 (34.3–56.3) (8)
0.042
47.5 (38.8–53.8) (8)
0.028
62.5 (44.0–64.3) (6)
0.109
Gleason 6
32.5 (20.3–36.5) (4)
38.5 (26.3–40.3) (2)
41.0 (38.0–50.0) (3)
45.0 (41.0–62.0) (3)
Gleason 7
32.0 (26.0–43.3) (4)
34.5 (23.5–56.0) (4)
46.0 (37.0–49.0) (3)
64.0 (47.3–61.0) (2)
Gleason 8
51.0 (1)
53.5 (36.0–44.3) (2)
61.5 (41.3–51.0) (2)
64.0 (1)
Hgb (g dl
±
1
)(n
)
All patients
15.9 (14.2–16.7) (7)
14.9 (13.3–16.9) (7)
15.9 (14.3–17.5) (5)
15.2 (14.3–15.8) (5)
Gleason 6
16.0 (15.9–16.7) (3)
16.2 (11.6–16.9) (2)
15.9 (15.1–17.2) (3)
15.4 (13.5–16.1) (3)
Gleason 7
14.6 (12.1–16.6) (4)
13.9 (13.0–16.1) (5)
15.6 (10.1–16.8) (2)
15.2 (1)
Gleason 8
—
—
—
15.1 (1)
Hct (%) (
n)
All patients
46.5 (42.1–50.2) (7)
44.2 (38.7–49.8) (7)
45.9 (42.8–51.8) (5)
44.9 (42.7–46.1) (5)
Gleason 6
47.4 (46.5–50.2) (3)
48.0 (34.6–49.9) (2)
45.9 (45.7–51.2) (3)
45.4 (41.2–46.7) (3)
Gleason 7
42.6 (36.4–49.5) (4)
40.9 (38.3–48.1) (5)
46.1 (29.9–49.5) (2)
44.2 (1)
Gleason 8
—
—
—
44.9 (1)
PSA (ng ml
±
1
)(n
)
All patients
0.88 (0.13–1.24) (9)
1.000
0.63 (0.25–1.36) (9)
0.484
0.66 (0.16–1.35) (6)
0.345
0.29 (0.05–0.43) (6)
0.753
Gleason 6
0.85 (0.16–0.88) (3)
0.93 (0.45–1.16) (2)
0.20 (0.03–1.12) (3)
0.28 (0.02–0.65) (3)
Gleason 7
0.91 (0.07–1.27) (5)
0.63 (0.08–1.36) (5)
0.92 (1)
0.18 (0.05–0.38) (2)
Gleason 8
1.22 (1)
1.31 (0.30–1.67) (2)
1.21 (0.30–1.52) (2)
0.36 (1)
Abbreviations: E, estradiol; FT, free testosterone; Hct, hematocrit; Hgb, hemoglobin; PSA, prostate-speci±c antigen; SHBG, sex hormone-binding globulin;
T, testosterone; TRT, testosterone replacement therapy.
All values are median (interquartile range) unless otherwise indicated.
P
-values represent comparisons between baseline and the time interval indicated.
Testosterone replacement after radiation treatment for prostate cancer
AW Pastuszak
et al
26
International Journal of Impotence Research (2013), 24 – 28
&
2013 Macmillan Publishers Limited